Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 25051-25060 Newer>

The Motley Fool August 1, 2007 Tom Taulli	Data Domain's Good Vibrations The newly public company continues to get traction as it replaces tape-backup technologies. For investors who like hypergrowth companies, this might be a good entry point to pick up some shares.
The Motley Fool August 1, 2007 Steven Mallas	"Shrek" Is a Dream for DreamWorks With other popular titles and another "Shrek" on the way, the animation studio looks like a good long-term bet for investors.
The Motley Fool August 1, 2007 Rich Smith	Blackboard Floored The educational software firm's guidance underwhelms investors.
The Motley Fool August 1, 2007 Rich Smith	L-3 Overtaken by Events Three recent contract awards from the U.S. government which may hold even more promise for L-3's future than did the news that management raised guidance last week. Why is it, again, that L-3 is down 3% post-earnings?
The Motley Fool August 1, 2007 Rick Aristotle Munarriz	Diller's in a Pickle at IAC The biggest opportunity at IAC lies in its Ask.com search engine. Investors, take note.
The Motley Fool August 1, 2007 Brian Lawler	Panacos' Plans There are still a lot of unresolved questions with Panacos' lead development program. At least investors will have more bevirimat efficacy and safety data to to tide them over until the drug's formulation issues can be worked out.
The Motley Fool August 1, 2007 Rick Aristotle Munarriz	What a Wild Ride Cedar Fair's Become The regional amusement park operator is no longer a steady stock.
The Motley Fool August 1, 2007 Sham Gad	Security Analysis 201: Intrinsic Value When you see a wide gap between Mr. Market's price and the intrinsic value of a business, and the gap is in your favor -- with intrinsic value being far higher than the stock price -- it makes sense to invest.
The Motley Fool August 1, 2007 Brian Lawler	ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth.
The Motley Fool July 31, 2007 David Meier	Panera: Crusty and Stale Despite great growth, Panera isn't much of a turnaround possibility. The only stock investors should be ordering is the one in the soup.
<Older 25051-25060 Newer> Return to current articles.